Japanese nationals have become increasingly jittery over traveling to China after several Japanese were targeted in violent attacks.Some of the products that Ken Kato sells though his funerary ...

Dublin organisations were among the big winners at the second Menopause Workplace Excellence Awards, staged in the capital ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

Electronic health record (EHR) documentation seen in primary care does not accurately reflect menopause symptom burden.

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on ...

AstraZeneca has bagged a cardiovascular disease candidate from China's CSPC Pharma in a deal potentially worth $2 billion.

The treatment of metabolic dysfunction-associated steatohepatitis (MASH) has proven challenging, with many compounds failing during development for various reasons. However, with the recent ...

Upstream asserts that verekitug could offer advantages over Tezpire, including potentially greater potency and longer dosing intervals. The company is testing intervals of 12 and 24 weeks in its ...

Cambridge’s Camp4 Therapeutics Inc. and Waltham’s Upstream Bio Inc. will both make their debuts on the public markets Friday.

The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer this year, the most since 2021.

Iota Biosciences, a subsidiary of Astellas Pharma, announced that it received FDA investigational device exemption (IDE) for ...